Amlodipine Besilate + Atorvastatin

Amlodipine and Atorvastatin is for patients in whom treatment is appropriate at the dose presented. These include patients with hypertension, chronic stable angina, and hypercholesterolemia (as an adjunct to diet). It is also used in hypertensive patients with multiple risk factors for CHD, to reduce the risk of nonfatal MI and nonfatal stroke. Amlodipine is indicated for the treatment of hypertension. It may be used alone or in combination with other antihypertensive agents. In Coronary Artery Disease (CAD), Amlodipine is indicated for chronic stable angina, and it may be used alone or in combination with other antianginal or antihypertensive agents. It is also indicated for confirmed or suspected vasospastic angina (Prinzmetal's or Variant Angina), either as monotherapy or in combination with other antianginal drugs. For angiographically documented CAD, Amlodipine is indicated in patients with recently documented CAD by angiography who have no heart failure and no ejection fraction below 40%. In these patients it reduces the risk of hospitalization due to angina and the risk of a coronary revascularization procedure. Atorvastatin is indicated as an adjunct to diet to reduce elevated total cholesterol, LDL-cholesterol, apolipoprotein B and triglyceride levels in patients with primary hypercholesterolemia (heterozygous familial and nonfamilial) and mixed dyslipidemia (Fredrickson Types lla and llb). It is also indicated as adjunctive therapy to diet for patients with elevated serum triglyceride levels (Fredrickson Type IV), and for patients with primary dysbetalipoproteinemia (Fredrickson Type III) who do not respond adequately to diet. In patients with homozygous familial hypercholesterolemia, Atorvastatin is used to reduce total-C and LDL-C, as an adjunct to other lipid lowering treatments (e.g. LDL apheresis) or if such treatments are unavailable. When a patient is in hospital for an acute coronary event, drug therapy can be considered at discharge if the LDL-C level is above 100 mg/dL (NCEP-ATP III). Before starting Atorvastatin, secondary causes of hypercholesterolemia should be excluded (e.g., poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, and alcoholism). A lipid profile should also be done to measure total-C, LDL-C, HDL-C, and TG.